Amgen announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel. The first randomized clinical trial for a KRASG12C inhibitor assessed the efficacy and safety of LUMAKRAS in 345 previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had received at minimum, prior platinum-based doublet chemotherapy and checkpoint inhibitor therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
270 USD | +0.22% | +0.39% | -6.26% |
Apr. 26 | Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe | MT |
Apr. 26 | Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.26% | 144B | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-11.77% | 143B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen Announces Topline Data from LUMAKRAS® Phase 3 Trial in Non-Small Cell Lung Cancer